Clinical trials: Common Wart
Common Warts, Common Warts (Verruca Vulgaris)
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102)…
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-2 (NCT07246590)
- Testing
- VP-102, Vehicle
- Where
- 17 sites in United States
- Volunteers
- 302 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Common Warts (Verruca Vulgaris), Common Warts
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4.
- Conditions
- Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-4 (NCT07457918)
- Testing
- Cantharidin
- Where
- 12 sites in United States, Japan
- Volunteers
- 250 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Common Warts, Common Warts (Verruca Vulgaris)
Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)
This is a Phase 2, open-label study (Study VP-CW-304; referred to as COVE-5 [Cantharidin and Occlusion in Verruca Epithelium 5]) to evaluate the safety and systemic exposure of YCANTH (VP-102) following a single 24-hour dermal…
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-5 (NCT07881952)
- Testing
- VP-102
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Common Warts, Common Warts (Verruca Vulgaris)
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208)…
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-3 (NCT07637734)
- Testing
- VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan)
- Where
- 20 sites in United States, Japan
- Volunteers
- 300 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Common Wart, Flat Wart
Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts
Human papillomavirus (HPV) infection is very common, as most people will experience infection during their lifetime. The most common manifestation of HPV infection is common warts. Common warts may appear at any age.
- Conditions
- Common Wart, Flat Wart, Plantar Wart
- Trial name
- EVAsION (NCT03977753)
- Testing
- 2LVERU® or 2LVERU® JUNIOR
- Where
- 6 sites in Belgium
- Volunteers
- 162 people
- Sponsor
- Labo'Life
Viral Wart, Plantar Wart
Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
The goal of this clinical trial is to learn if injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts works to clear them in people aged 12 and older with common, plantar, flat, or periungual (around the…
- Conditions
- Viral Wart, Plantar Wart, Common Warts (Verruca Vulgaris), Common Wart
- Trial name
- NCT07448844
- Testing
- Intralesional Acyclovir, Intralesional Vitamin D3
- Where
- 2 sites in Pakistan
- Volunteers
- 40 people
- Sponsor
- Riphah International University
Common Warts (Verruca Vulgaris)
New Treatment of Common Wart
this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts.
- Trial name
- NCT07543926
- Testing
- PRF group, Vitamin D
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Sohag University
Common Warts
Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart
Warts caused by the human papillomavirus (HPV) are one of the most common skin conditions among children. The prevalence of warts in school-aged children ranges from 10 to 20 percent.
- Trial name
- NCT06737406
- Testing
- Topical 5% fluorouracil cream, Topical 0.005% calcipotriol ointment
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Mazandaran University of Medical Sciences
Common Warts, Plantar Warts
Salicylic Acid Wart Patch for the Treatment of Common Warts and Plantar Warts
Common and plantar warts are a type of skin lesion caused by infection with the human papilloma virus. The incidence of warts is relatively high, with an estimated few to several per cent of the adult population affected.
- Trial name
- NCT06958237
- Testing
- salicylic acid wart patches
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Langsteiner sp. z o.o.
Common Warts (Verruca Vulgaris)
Candin for the Treatment of Common Warts
The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo.
- Trial name
- NCT05889845
- Testing
- Candin, Intradermal Solution
- Where
- 18 sites in United States
- Volunteers
- 330 people
- Sponsor
- Nielsen BioSciences, Inc.
Verruca Vulgaris, Warts
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
- Conditions
- Verruca Vulgaris, Warts, Common Wart
- Trial name
- NCT05799157
- Testing
- VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch
- Where
- 16 sites in United States
- Volunteers
- 153 people
- Sponsor
- Veradermics, Inc.
Warts, Plantar Wart
Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts.
The principal aim of this study is to evaluate the efficacy and the safety of the tested product on common and plantar wart after 35 days of treatment.
- Conditions
- Warts, Plantar Wart, Common Wart
- Trial name
- NCT06214559
- Testing
- Sérum VERRUPRO
- Where
- 2 sites in Tunisia
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Swiss Footcare Laboratories - Poderm Professional
Common Wart
Sclerotherapy and Candida Antigen in Treatment of Common Warts
This study aims to evaluate the efficacy and safety of intralesional injections of candida antigen, polidocanol sclerotherapy and combined candida antigen with polidocanol in treatment of patients with common warts.
- Trial name
- NCT06749665
- Testing
- polidacanol 3%, candida antigen
- Where
- Egypt
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Sohag University
Common Wart, Warts Hand
Cantharidin and Occlusion in Verruca Epithelium
This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common…
- Conditions
- Common Wart, Warts Hand, Warts, Papillomavirus Infections
- Trial name
- COVE-1 (NCT03487549)
- Testing
- VP-102 Cantharidin topical film forming solution, VP-102 Cantharidin, topical film forming solution
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Common Wart
OM202JP Clinical Study of KNP2002
The goal of this clinical trial is to evaluate safety and efficacy of KNP2002 in patients with common warts aged 15 to 50 years old.
- Trial name
- NCT05896215
- Testing
- KNP2002
- Where
- 15 sites in Japan
- Volunteers
- 159 people
- Sponsor
- KinoPharma Inc.
Common Wart
Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.
- Trial name
- NCT01796795
- Testing
- Vehicle gel, SR-T100 gel with 1.0% of SM, SR-T100 gel with 2.3% of SM
- Volunteers
- 102 people
- Sponsor
- G&E Herbal Biotechnology Co., LTD
Cutaneous Common Warts
A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).
- Trial name
- NCT02971891
- Testing
- CLS006 (Furosemide) Topical Gel, Vehicle Topical Gel
- Where
- 30 sites in United States
- Volunteers
- 484 people
- Sponsor
- Maruho Co., Ltd.
Cutaneous Common Warts
A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).
- Trial name
- NCT03259620
- Testing
- CLS006, CLS006 Vehicle
- Where
- 35 sites in United States
- Volunteers
- 491 people
- Sponsor
- Maruho Co., Ltd.
Common Wart, Plantar Wart
Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts
This is a Post-Market clinical Follow-up investigation to evaluate the safety and performed of the medical device Wortie Freeze Plus in the treatment of common and plantar warts.
- Trial name
- NCT05115669
- Testing
- Wortie freeze plus
- Where
- Poland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Karo Pharma AB
Intralesional Versus Intramuscular Hepatitis B Vaccine for Multiple Common Warts
Intralesional Versus Intramuscular Hepatitis B Vaccine Immunotherapy for Warts
Assessment of the effectiveness of intralesional and intramuscular hepatitis B vaccine in treatment of multiple common warts.
- Trial name
- NCT05326152
- Testing
- hepatitis B vaccine immunotherapy of common warts (GeneVac-B 10 ml vial, Serum Institute of India Ltd., Pune, India), Intralesional saline
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Zagazig University